Skip to main content
editorial
. 2019 Jul 11;3(1):1–4. doi: 10.1017/cts.2019.375
Key
AK CI C LP EB
1. Did you recruit participants for your study? (yes/no) X
If yes, expand (race, age, disease)
2. Did you partner with any community groups for your study? (yes/no) X
If yes, expand (disease specific, race)
3. Did you develop a new investigational drug? (yes/no) X
If yes, expand
If yes, has the application been accepted by the FDA?
Has it shown any benefits?
4. Did you develop any mobile applications/software as a result of your work (yes/no) X
If yes, name of app or software
If yes, expand (who used your app, age group)
5. Did you conduct any clinical trials (as a scholar or after completing the KL2)? (yes/no) X
If yes, expand on the trial
6. Did you develop any algorithms or instrument as a result of the research you did as a KL2 scholar? (yes/no) X
If yes, expand
Is anyone using algorithm or instrument?
7. Did your research study findings result in the development of materials to assist with healthcare decision-making? (yes/no) X
If yes, expand
8. Was a biological material application generated by the research study? (yes/no) X
If yes, expand
9. Has your research been used in the development of guidelines? (yes/no) X
If yes, expand
10. Has your research been used or cited in a policy development? (yes/no) X
If yes, expand
Were you invited to testify based on your research? (yes/no) X
If yes, expand
Were any changes made as a result of your testimony?
Did your research result in cost reduction of health care delivery costs? (yes/no) X
If yes, expand
Did your research result in a cost-effective intervention for a condition? (yes/no) X
If yes, expand

Did your research result in anything else not mentioned here?

KEY: AK, advancement of knowledge; CI, clinical implementation; C, community benefit; LP, legislation and policy; EB, economic benefit.